
==== Front
Neurooncol Adv
Neurooncol Adv
noa
Neuro-Oncology Advances
2632-2498
Oxford University Press US

10.1093/noajnl/vdae090.048
vdae090.048
Final Category: Multimodality Approaches
AcademicSubjects/MED00300
AcademicSubjects/MED00310
MMOD-04 LASER INTERSTITIAL THERMAL THERAPY (LITT) AND IMMUNOTHERAPY SYNERGY FOR RECURRENT BRAIN CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS
Sharma Eshita Brigham and Women’s Hospital, Boston/MA, USA

Sahin Oguz Kagan Acibadem Mehmet Ali Aydinlar University School of Medicine, Istanbul, Turkey

Łajczak Paweł Medical University of Silesia, Katowice, Poland

Ahmed Aisha Rizwan Jinnah Medical and Dental College, Karachi, Pakistan

Silva Yasmin Picanço University of Debrecen, Debrecen, Hungary

Ayesha Ayesha Shifa College of Medicine, Islamabad, Pakistan

Chatterjee Anoushka University of Debrecen, Debrecen, Hungary

Raake Mohammed Annamalai University, Chennai, India

Petry Iago Nathan Simon Unisul (University of Southern Santa Catarina), Palhoça/Santa Catarina, Brazil

8 2024
02 8 2024
02 8 2024
6 Suppl 1 2024 SNO/ASCO CNS Metastases Conference i16i16
© The Author(s) 2024. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
2024
https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

Abstract

BACKGROUND

The confluence of laser interstitial thermal therapy (LITT) with immunotherapeutic approaches represents a promising avenue for the management of recurrent brain metastases and glioblastoma. However, the potential synergy between these modalities prompts a thorough examination of their adverse effects. This meta-analysis seeks to evaluate the literature to elucidate the adverse effects associated with the combined use of LITT and immunotherapy in treating recurrent gliomas.

METHODS

Thorough systematic searches were performed on PubMed, Embase, and Web of Science databases using predefined search terms to identify pertinent studies. Inclusion criteria comprised case-control studies, cohort studies, and randomized controlled trials investigating the combined utilization of laser interstitial thermal therapy (LITT) with immunotherapy, among adult patients diagnosed with recurrent brain metastases and recurrent glioblastoma. Our analysis specifically targeted adverse events (AEs) as the primary outcome of interest.

RESULTS

Our systematic review included four studies, including one randomized controlled trial (RCT), one case-control study, and two prospective cohort studies, with a total of 162 patients. Utilizing a random effects model in STATA, we performed a single-arm analysis of adverse events experienced by 56 patients across 3 studies and reported the combination of LITT with immunotherapy for managing recurrent gliomas demonstrated no significant proportion of adverse effects (Proportion= 0.11, 95% CI= -0.02-0.25, P=0.09).

CONCLUSION

When evaluating adverse effects, the combined approach of LITT with immunotherapy in managing recurrent brain metastases and glioblastoma showed no notable significant percentage of patients incurring adverse events, thereby implying a potential comparable safety profile to conventional treatment modalities. However, further research is warranted to test differences in the incidence of adverse events from LITT with immunotherapy versus a control.

LITT
immunotherapy
brain cancer
systematic review
meta-analysis
==== Body
pmc
